IWM
CYTK icon

IHT Wealth Management’s Cytokinetics CYTK Stock Holding History

IHT Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-800
Closed -$6K – 621
2018
Q1 		$6K Hold
800
– – ﹤0.01% 1295
2017
Q4 		$7K Buy
+800
New +$9.08K ﹤0.01% 1261

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

IHT Wealth Management's CYTK Position: Q2 2018 in Review

IHT Wealth Management sold out of Cytokinetics (CYTK) in Q2 2018, closing a stake of 800 shares — an estimated $6K sold.

IHT Wealth Management first reported a position in CYTK in Q4 2017 and held it in 2 quarters. The position peaked at $7K in Q4 2017. 126 funds tracked by Wall St. Rank hold CYTK as of Q2 2018.

  • IHT Wealth Management reported no remaining Cytokinetics position as of Q2 2018 after selling out during the quarter.
  • IHT Wealth Management sold 800 Cytokinetics shares in Q2 2018, an estimated $6K.
  • IHT Wealth Management first reported a position in Cytokinetics in Q4 2017 and held it in 2 quarters.
  • IHT Wealth Management's Cytokinetics position peaked at $7K in Q4 2017.
  • 126 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.